ORIC Pharmaceuticals, Inc.

What they do

ORIC is advancing a pipeline of clinical-stage product candidates targeting resistance mechanisms in cancer. Its lead candidate, rinzimetostat, is a PRC2/EED inhibitor in Phase 3 for metastatic castration-resistant prostate cancer (mCRPC), and enozertinib is a brain-penetrant EGFR inhibitor in Phase 1b for non-small cell lung cancer (NSCLC). The company conducts its own R&D and relies on collaborations for supply of certain combination agents.

Revenue drivers

• No approved products — The company has no commercial revenue; it is a clinical-stage biotech entirely dependent on financing.
• Rinzimetostat (ORIC-944) — Most advanced program; Phase 3 Himalayas-1 trial initiated in mCRPC; licensed from Mirati.
• Enozertinib (ORIC-114) — Phase 1b program in EGFR-mutant NSCLC; licensed from Voronoi; potential registrational trial anticipated.

Recent performance

For Q2 2026, ORIC reported R&D expenses of $36.3 million, up from $30.5 million in Q2 2025, and $67.7 million for the first half of 2026 versus $55.2 million in the prior-year period. The company had cash, cash equivalents, and investments of $387.6 million as of June 30, 2026, which included $59.9 million in net proceeds from an at-the-market offering. Net losses have widened annually from $78.7 million in 2021 to $129.5 million in 2025, with operating cash flow negative at $111.0 million in 2025.

Strategy

ORIC is focused on advancing rinzimetostat to a Phase 3 registrational trial and preparing enozertinib for a potential registrational trial. The company is leveraging collaborations with Bayer and Johnson & Johnson to supply combination agents for its trials. It is also exploring enozertinib as a single agent and in combination with amivantamab or chemotherapy. Management intends to retain global development and commercial rights to its product candidates.

Risks

• Clinical and regulatory failure — No product is approved, and rinzimetostat's Phase 3 trial (Himalayas-1) could fail to meet endpoints, delaying or preventing approval.
• Financing dependence — With no revenue and negative cash flow, the company relies on equity raises and collaborations; the current cash runway extends only into 2H 2028.
• Competition — Competitor PRC2 inhibitors and standard-of-care therapies in mCRPC could limit rinzimetostat's commercial opportunity if approved.
• Reliance on third parties — ORIC depends on third parties for clinical trials and manufacturing, including Bayer and Johnson & Johnson for combination agents.

Outlook

Management anticipates a rinzimetostat program update in 2H 2026 and enozertinib clinical data (1L EGFR atypical monotherapy, exon 20 insertion monotherapy, and combination with amivantamab) in 2H 2026. The Himalayas-1 Phase 3 trial, initiated in July 2026, is expected to enroll approximately 600 patients across 25 countries. Cash and investments of approximately $388 million are expected to fund operations into 2H 2028, beyond the anticipated primary endpoint readout from the first Phase 3 trial.